A&D Medical rolls out new monitoring devices
SAN JOSE, Calif. A&D Medical on Wednesday introduced three new wireless telehealth and wellness devices featuring ANT technology.
A&D Medical’s monitoring devices with ANT wireless technology are essential feedback components for wellness coaching and health tracking, the company stated. Suitable for Web-based employee health programs, disease management, prevention programs and consumer wellness solutions, A&D Medical’s ANT devices enable a richer, more data-driven experience for both program administrators and end users.
These three A&D Medical products are designed for use with both mHealth and eHealth applications. Using ANT technology, the new products include a tri-axial activity monitor, precision personal health scale and an automatic blood pressure monitor. Each of these products feature an ANT wireless radio with automatic data transmission for seamless health metrics tracking.
ANT is a proven protocol and silicon solution for ultra-low-power practical wireless networking applications. It is designed for ease of use, efficiency and scalability with an installed base of more than 11 million nodes to date.
Warner Chilcott’s Atelvia receives FDA approval
ARDEE, Ireland The Food and Drug Administration has approved a new formulation of a drug for osteoporosis made by Warner Chilcott, the drug maker said Monday.
Warner Chilcott announced the approval of Atelvia (risendronate sodium), a treatment for postmenopausal osteoporosis, which it plans to launch early next year. The drug is a delayed-release formulation of Actonel.
“The approval of Atelvia represents an exciting addition to the Actonel franchise, as well as our women’s healthcare product portfolio,” Warner Chilcott president and CEO Roger Boissonneault said. “We believe the dosing convenience of Atelvia sets it apart from other treatment options for osteoporosis patients, and provides an opportunity to regain market share in the United States in this segment.”
Tylenol gets ‘precise’
NEW YORK McNeil Consumer Healthcare recently parlayed its Tylenol brand franchise into external analgesics.
Labeled Tylenol Precise, McNeil introduced two SKUs into the external analgesic space — a patch and a cream. The air-activated heat therapy will go up against Pfizer Consumer’s Thermacare, which is experiencing a resurgence in sales under its relatively new stewardship (Wyeth Consumer, now part of Pfizer, had purchased the rights to Thermacare from Procter & Gamble two years ago).
Both the Tylenol Precise cream and Tylenol Precise patch retail for around $7.99.